Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies.
| Title: | Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. |
|---|---|
| Authors: | Gonzalez MC; Department of Quality and Health Technology, Faculty of Health Sciences, University of Stavanger, Stavanger, Norway.; The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.; Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.; Ashton NJ; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Department of Old Age Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom.; Gomes BF; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Tovar-Rios DA; Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.; Blanc F; Memory Resource and Research Centre, Geriatrics Day Hospital, Geriatrics Department, University Hospital of Strasbourg, Strasbourg, France.; Karikari TK; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Mollenhauer B; Department of Neurology, University Medical Center Goettingen, Goettingen, Germany, and Paracelsus-Elena-Klinik, Kassel, Germany.; Pilotto A; Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.; Lemstra A; Amsterdam Alzheimer Center, Amsterdam University Medical Centers, Amsterdam, the Netherlands.; Paquet C; Université de Paris, Neurology Center, Assistance Publique Hôpitaux de Paris, Lariboisière Fernand-Widal Hospital, INSERMU1144, Paris, France.; Abdelnour C; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain.; Kramberger MG; University Medical Centre Ljubljana, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.; Bonanni L; Department of Medicine and Aging Sciences, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy.; Vandenberghe R; Laboratory for Cognitive Neurology, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium.; Hye A; Department of Old Age Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom.; Blennow K; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Zetterberg H; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.; UK Dementia Research Institute at UCL, London, UK.; Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.; Aarsland D; Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.; Department of Old Age Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom. |
| Corporate Authors: | European–Dementia With Lewy Bodies (E-DLB) Consortium |
| Source: | JAMA neurology [JAMA Neurol] 2022 Jan 01; Vol. 79 (1), pp. 32-37. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101589536 Publication Model: Print Cited Medium: Internet ISSN: 2168-6157 (Electronic) Linking ISSN: 21686149 NLM ISO Abbreviation: JAMA Neurol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Chicago, IL : American Medical Association, [2013]- |
| MeSH Terms: | Cognitive Dysfunction/*blood ; Cognitive Dysfunction/*pathology ; Lewy Bodies/*pathology ; Lewy Body Disease/*blood ; Lewy Body Disease/*pathology ; tau Proteins/*blood; Cognitive Dysfunction/complications ; Lewy Body Disease/complications ; Aged ; Female ; Humans ; Male ; Phosphorylation |
| Abstract: | Importance: Plasma phosphorylated tau (p-tau) has proven to be an accurate biomarker for Alzheimer disease (AD) pathologic characteristics, offering a less expensive and less invasive alternative to cerebrospinal fluid (CSF) and positron emission tomography biomarkers for amyloid-β and tau. Alzheimer disease comorbid pathologic characteristics are common and are associated with more rapid cognitive decline in patients with dementia with Lewy bodies (DLB); therefore, it is anticipated that plasma p-tau concentrations may have utility in assessing cognitive impairment in individuals with this disorder.; Objective: To measure the concentrations of plasma p-tau (p-tau181 and p-tau231) and evaluate their associations with cognitive decline in individuals with probable DLB.; Design, Setting, and Participants: This multicenter longitudinal cohort study included participants from the European-DLB (E-DLB) Consortium cohort enrolled at 10 centers with harmonized diagnostic procedures from January 1, 2002, to December 31, 2020, with up to 5 years of follow-up. A total of 1122 participants with plasma samples were available. Participants with acute delirium or terminal illness and patients with other previous major psychiatric or neurologic disorders were excluded, leaving a cohort of 987 clinically diagnosed participants with probable DLB (n = 371), Parkinson disease (n = 204), AD (n = 207), as well as healthy controls (HCs) (n = 205).; Main Outcomes and Measures: The main outcome was plasma p-tau181 and p-tau231 levels measured with in-house single molecule array assays. The Mini-Mental State Examination (MMSE) was used to measure cognition.; Results: Among this cohort of 987 patients (512 men [51.9%]; mean [SD] age, 70.0 [8.8] years), patients with DLB did not differ significantly regarding age, sex, or years of education from those in the AD group, but the DLB group was older than the HC group and included more men than the AD and HC groups. Baseline concentrations of plasma p-tau181 and p-tau231 in patients with DLB were significantly higher than those in the HC group but lower than in the AD group and similar to the Parkinson disease group. Higher plasma concentrations of both p-tau markers were found in a subgroup of patients with DLB with abnormal CSF amyloid-β42 levels compared with those with normal levels (difference in the groups in p-tau181, -3.61 pg/mL; 95% CI, -5.43 to -1.79 pg/mL; P = .049; difference in the groups in p-tau231, -2.51 pg/mL; 95% CI, -3.63 to -1.39 pg/mL; P = .02). There was no difference between p-tau181 level and p-tau231 level across confirmed AD pathologic characteristcs based on reduced Aβ42 level in CSF in individuals with DLB. In DLB, a significant association was found between higher plasma p-tau181 and p-tau231 levels and lower MMSE scores at baseline (for p-tau181, -0.092 MMSE points; 95% CI, -0.12 to -0.06 MMSE points; P = .001; for p-tau231, -0.16 MMSE points; 95% CI, -0.21 to -0.12 MMSE points; P |
| Comments: | Erratum in: JAMA Neurol. 2022 Mar 1;79(3):313. doi: 10.1001/jamaneurol.2021.5446.. (PMID: 35099522) |
| Grant Information: | United Kingdom DH_ Department of Health; R01 AG068398 United States AG NIA NIH HHS |
| Contributed Indexing: | Investigator: C Carrarini; M Russo; A Vrillon; E Cognat; J Dumurgier; C Hourregue; S Gaubert; M Porché; M Lilamand; C Teunissen; K Bolsewig; P Anthony; B Cretin; C Demunyck; C Martin; C Muller; N Philippi; A Ravier; A Botzung; T Albasser; E Epp-Ehrhard; G Jung; J Merignac; L Monjoin; K Poesen; I Cleynen; M Boada; A Orellana |
| Substance Nomenclature: | 0 (MAPT protein, human); 0 (tau Proteins) |
| Entry Date(s): | Date Created: 20211122 Date Completed: 20220218 Latest Revision: 20221123 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC8609462 |
| DOI: | 10.1001/jamaneurol.2021.4222 |
| PMID: | 34807233 |
| Database: | MEDLINE |
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't